Zuellig Pharma 在泰国推出礼来公司的肥胖和糖尿病药物
The launch of Mounjaro® in Thailand provides a much-needed advanced therapeutic option for the growing number of patients suffering from obesity and type 2 diabetes in the country.
Launched Eli Lilly's Mounjaro® (tirzepatide) for obesity and diabetes in Thailand.
Zuellig Pharma 已在泰国推出礼来公司（Eli Lilly）的创新肥胖和糖尿病药物 Mounjaro®（tirzepatide）。这标志着在为管理这些慢性病的患者提供先进治疗方案方面迈出了重要一步，利用 Zuellig Pharma 将新型药物引入泰国市场的专业知识，改善患者护理。
The launch of Mounjaro® in Thailand provides a much-needed advanced therapeutic option for the growing number of patients suffering from obesity and type 2 diabetes in the country. This aligns with regional efforts to combat the rising prevalence of these metabolic diseases, offering improved patient outcomes and quality of life through access to innovative treatments.
This product launch in Thailand addresses the significant and growing burden of obesity and diabetes in the APAC region, offering a new treatment option for patients.
此信号在行业全局中的位置。
https://www.zuelligpharma.com/news-insights/zuellig-pharma-launches-lillys-innovative-obesity-and-diabetes-medicine-in-thailand
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录